Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2013 1
2014 3
2015 2
2016 1
2017 1
2019 1
2021 2
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.
Guglielmelli P, Maccari C, Sordi B, Balliu M, Atanasio A, Mannarelli C, Capecchi G, Sestini I, Coltro G, Loscocco GG, Rotunno G, Angori E, Borri FC, Tefferi A, Vannucchi AM. Guglielmelli P, et al. Among authors: balliu m. Blood Cancer J. 2023 Jan 30;13(1):21. doi: 10.1038/s41408-023-00786-x. Blood Cancer J. 2023. PMID: 36710362 Free PMC article. No abstract available.
CALR mutation burden in essential thrombocythemia and disease outcome.
Guglielmelli P, Szuber N, Gangat N, Capecchi G, Maccari C, Harnois M, Karrar O, Abdelmagid M, Balliu M, Nacca E, Atanasio A, Sestini I, Désilets A, Loscocco GG, Rotunno G, Busque L, Tefferi A, Vannucchi AM. Guglielmelli P, et al. Among authors: balliu m. Blood. 2024 Mar 28;143(13):1310-1314. doi: 10.1182/blood.2023023428. Blood. 2024. PMID: 38252902
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model.
Bianchi E, Rontauroli S, Tavernari L, Mirabile M, Pedrazzi F, Genovese E, Sartini S, Dall'Ora M, Grisendi G, Fabbiani L, Maccaferri M, Carretta C, Parenti S, Fantini S, Bartalucci N, Calabresi L, Balliu M, Guglielmelli P, Potenza L, Tagliafico E, Losi L, Dominici M, Luppi M, Vannucchi AM, Manfredini R. Bianchi E, et al. Among authors: balliu m. Leukemia. 2023 May;37(5):1068-1079. doi: 10.1038/s41375-023-01867-3. Epub 2023 Mar 16. Leukemia. 2023. PMID: 36928007 Free PMC article.
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis.
Genovese E, Mirabile M, Rontauroli S, Sartini S, Fantini S, Tavernari L, Maccaferri M, Guglielmelli P, Bianchi E, Parenti S, Carretta C, Mallia S, Castellano S, Colasante C, Balliu M, Bartalucci N, Palmieri R, Ottone T, Mora B, Potenza L, Passamonti F, Voso MT, Luppi M, Vannucchi AM, Tagliafico E, Manfredini R, On Behalf Of The Mynerva MYeloid NEoplasms Research Venture Airc. Genovese E, et al. Among authors: balliu m. Antioxidants (Basel). 2022 Jan 5;11(1):113. doi: 10.3390/antiox11010113. Antioxidants (Basel). 2022. PMID: 35052617 Free PMC article.
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2.
Romagnoli S, Bartalucci N, Gesullo F, Balliu M, Bonifacio S, Fernandez AGL, Mannelli F, Bolognini D, Pelo E, Mecucci C, Guglielmelli P, Vannucchi AM. Romagnoli S, et al. Among authors: balliu m. Biomark Res. 2021 Nov 12;9(1):83. doi: 10.1186/s40364-021-00337-1. Biomark Res. 2021. PMID: 34772467 Free PMC article.
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.
Salati S, Genovese E, Carretta C, Zini R, Bartalucci N, Prudente Z, Pennucci V, Ruberti S, Rossi C, Rontauroli S, Enzo E, Calabresi L, Balliu M, Mannarelli C, Bianchi E, Guglielmelli P, Tagliafico E, Vannucchi AM, Manfredini R. Salati S, et al. Among authors: balliu m. Sci Rep. 2019 Jul 22;9(1):10558. doi: 10.1038/s41598-019-46843-z. Sci Rep. 2019. PMID: 31332222 Free PMC article.
16 results